Jacobi Capital Management’s Marker Therapeutics MRKR Stock Holding History

Jacobi Capital Management’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-40	Closed	-$1K	–	969
2021 Q3	$1K	Hold	40	–	–	﹤0.01%	1399
2021 Q2	$1K	Hold	40	–	–	﹤0.01%	1345
2021 Q1	$1K	Hold	40	–	–	﹤0.01%	1315
2020 Q4	$1K	Hold	40	–	–	﹤0.01%	1245
2020 Q3	$1K	Hold	40	–	–	﹤0.01%	1196
2020 Q2	$1K	Hold	40	–	–	﹤0.01%	1157
2020 Q1	$1K	Hold	40	–	–	﹤0.01%	1061
2019 Q4	$1K	Hold	40	–	–	﹤0.01%	1020
2019 Q3	$2K	Hold	40	–	–	﹤0.01%	945
2019 Q2	$3K	Hold	40	–	–	﹤0.01%	891
2019 Q1	$3K	Hold	40	–	–	﹤0.01%	848
2018 Q4	$2K	Hold	40	–	–	﹤0.01%	856
2018 Q3	$4K	Hold	40	–	–	﹤0.01%	824
2018 Q2	$4K	Buy	+40	New	+$2.04K	﹤0.01%	856

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jacobi Capital Management's MRKR Position: Q4 2021 in Review

Jacobi Capital Management sold out of Marker Therapeutics (MRKR) in Q4 2021, closing a stake of 40 shares — an estimated $1K sold.

Jacobi Capital Management first reported a position in MRKR in Q2 2018 and held it in 14 quarters. The position peaked at $4K in Q3 2018. 64 funds tracked by Wall St. Rank hold MRKR as of Q4 2021.

Jacobi Capital Management reported no remaining Marker Therapeutics position as of Q4 2021 after selling out during the quarter.
Jacobi Capital Management sold 40 Marker Therapeutics shares in Q4 2021, an estimated $1K.
Jacobi Capital Management first reported a position in Marker Therapeutics in Q2 2018 and held it in 14 quarters.
Jacobi Capital Management's Marker Therapeutics position peaked at $4K in Q3 2018.
64 funds tracked by Wall St. Rank held Marker Therapeutics as of Q4 2021.

Based on Jacobi Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.